A large, multicentre, observational, post-marketing surveillance study of the 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice for assisted reproductive technology

Table 3 Oocyte pick-up (OPU), embryo transfer (ET), and pregnancy rates for assisted reproductive technology cycles

Outcome	Age subgroup		All patients
Outcome	≤35 years	>35 years	All patients
hCG administered, n (%)	679 (98.1) (n = 692)	1494 (97.8) (n = 1528)	2173 (97.9) (n = 2220)
OPU attempted, n (%)	670 (96.8)(n = 692)	1438 (94.1) (n = 1528)	2108 (95.0) (n = 2220)
Number of oocytes retrieved, mean (SD) ^a	9.3 (5.85) (n = 670)	7.4 (5.07) (n = 1438)	8.0 (5.40) (n = 2108)
ET performed, n (%)	617 (89.2) (n = 692)	1215 (79.5) (n = 1528)	1832 (82.5) (n = 2220)^b
Number of embryos transferred, mean (SD) ^c	2.0 (0.51) (n = 617)	2.0 (0.65) (n = 1215)	2.0 (0.60) (n = 1832)
Implantation achieved, n (%)^d	346 (29.3) (n = 1179)	405 (17.4) (n = 2323)	751 (21.4) (n = 3502)
Clinical pregnancy per ET cycle, n (%)	255 (41.3) (n = 617)	319 (26.26) (n = 1215)	574 (31.3) (n = 1832)

The study evaluated data for 2220 assisted reproductive technology cycles; the percentages given in the table were calculated from different denominators as indicated.
^aOPU cycles.
^bET was not performed in 388 cycles.
^cET cycles.
^dImplantation rate is defined as the number of (intra- and extra-uterine) gestational sacs/number of transferred embryos.
hCH = human chorionic gonadotrophin; SD = standard deviation.

ISSN: 1477-7827